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Available online 10 August 2017Atrial fibrillation (AF) is themost common sustained arrhythmia associated with several cardiac risk factors, but
increasing evidences indicated a genetic component. Indeed, genetic variations of the atrial specific KCNA5 gene
have been identified in patients with early-onset lone AF. To investigate the molecular mechanisms underlying
AF, we reprogrammed to pluripotency polymorphonucleated leukocytes isolated from the blood of a patient car-
rying a KCNA5 p.D322H mutation, using a commercially available non-integrating system. The generated iPSCs
expressed pluripotency markers and differentiated toward cells belonging to the three embryonic germ layers.
Moreover, the cells showed a normal karyotype and retained the p.D322H mutation.mming
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Wegenerated a human cellular atrialfibrillationmodel starting from
a patient carryingKCNA5 p.D322Hmutation, already described as a gain
of function mutation (Christophersen et al., 2013). We believe that the
analysis of iPSC-derivedmutated cardiomyocyteswill contribute to elu-
cidate the molecular mechanisms underlying AF.
Resource details
UNIBSi001-A cell line was generated from patient's isolated poly-
morphonuclear leukocytes under feeder-free culture conditions. Totp://creativecommons.org/licenses/by-nc-nd/4.0/).
30 C. Mora et al. / Stem Cell Research 24 (2017) 29–32obtain iPSC cells we infected blood cells using the CytoTune 2.0 iPS Sen-
dai Reprogramming Kit (Thermo Fisher Scientific) which employs the
non-integrating Sendai virus (SeV) to deliver Yamanaka's factors
OCT4, SOX2, KLF4, and cMYC. Once the cell line was stabilized we eval-
uate the presence of contaminatingmycoplasma by PCR analysis aswell
as the loss of the SeV used for the reprogramming procedure by reverse
transcriptase PCR. Results are illustrated in Fig. 1A and indicate that
UNIBSi001-A cell line is both mycoplasma- and SeV-free. The presence
of numerical or structural chromosome abnormalities was evaluatedFig. 1.Molecular analysis ofusing standard QFQ-banding that revealed a normal 46,XY karyotype
of the cell line (Fig. 1B). Moreover, the persistence of the patient's
DNA mutation was confirmed by iPSC Sanger sequencing. As shown in
Fig. 1C, UNIBSi001-A iPSCs carry the heterozygosity in KCNA5 gene
that leads to the p.D322H mutation.
Next, the expression of the endogenous pluripotent transcription
factors was evaluated by quantitative PCR, using the primers reported
in Table 2,while the presence of the related proteins, aswell as the pres-
ence of additional stem cell markers, was evaluated byUNIBSi001-A iPSC line.
31C. Mora et al. / Stem Cell Research 24 (2017) 29–32immunofluorescence staining of iPSC colonies using the antibodies
listed in Table 2. At variance with PBMC, UNIBSi001-A iPSCs express
high levels of endogenous OCT4, SOX2, and NANOG, fully comparable
to those of a control iPSC line (Fig. 1D). Moreover, the resulting proteins
are correctly shown in the nuclear compartment of the cells, while addi-
tional SSEA3 and Tra-1-81 markers are properly present on cell surface
(Fig. 1E). Flow cytometry using SSEA4 and Tra-1-81 antibodies revealed
a pluripotent population higher than 94% (Fig. 1F).
Following the verification of pluripotencymarker expression, we in-
vestigated the UNIBSi001-A iPSC spontaneous differentiation capacity
in the three-dimensional structures called embryoid bodies (EBs). EBs
were left in suspension for seven days and then allowed to adhere to a
standard tissue culture surface. After two weeks, cells were fixed and
immunofluorescence was performed. The in vitro EB formation assay
confirmed the spontaneous differentiation capacity toward the three
germ layers of the UNIBSi001-A iPSC as demonstrated by the expression
of ectodermal (TUBB3), mesodermal (alpha-smooth muscle actin,
α-SMA) and endodermal (alpha-fetoprotein, AFP) markers (Fig. 1E).
In conclusion, we generated an iPSC line carrying the KCNA5 gene
p.D322H variant that has been previously described as a gain-of-func-
tion mutation identified in an AF patient. In Table 1, STR analysis that
uniquely identify UNIBSi001-A iPSCs has been reported. Potentially,
the study of the molecular basis of AF will strongly benefit by the anal-
ysis of the cardiomyocytes derived from UNIBSi001-A iPSCs, where the
mutation is inserted in the correct pathological genetic background of
the patient.
Materials and methods
Reprogramming of peripheral blood mononuclear cells (PBMC)
Peripheral bloodwas collected from a clinically diagnosed 35-years-
old male patient suffering from atrial fibrillation harboring the KCNA5
p.D322H mutation. PBMC were isolated by Ficoll-Paque® PLUS density
gradient centrifugation using SepMate™-15 - specialized PBMC Isola-
tion Tube (Stem Cell Technologies) and maintained in StemPro®-34
SFMMedium (Thermo Fisher Scientific) supplementedwith StemSpam
CC100 cytokines (Stem Cell Technologies) for 4 days.
Then, PBMCs were transduced using the CytoTune 2.0 iPS Sendai
Reprogramming Kit (Thermo Fisher Scientific) following
manufacturer's instructions. hiPSC colonies were manually picked be-
tween day 17 and day 28 post infection, and expanded for further
characterization.
iPSC karyotyping
Cells undergoing active cell division were blocked at metaphase by
adding 10 μg/mL of colcemid (KaryoMax, Gibco Co. BRL) to culture me-
dium for 3 h at 37 °C. Then, cells were trypsinized, swollen by exposureTable 1
Characterization and validation of UNIBSi001-A iPSC line.
Classification Test Result
Morphology Photography Visual record of the line: normal
Phenotype Immunocytochemistry Expression of pluripotency markers OCT4, SO




46XY, at 400–450 band resolution











Immunocytochemical expression of alpha fet
(ectodermal germ layer), and alpha Smoothto hypotonic 75 mM KCL solution, fixed with methanol/glacial acetic
acid (3:1), and dropped onto glass slides. Cytogenetic analysis was per-
formed using QFQ-banding at 400–450 bands resolution according to
the International System for Human Cytogenetic Nomenclature (ISCN
2016). A minimum of 20 metaphase spreads and 3 karyograms were
analyzed.
iPSC genotyping
Genomic DNA from patient-derived iPSC was extracted using
DNeasy blood and tissue kit (Qiagen) and the analysis of the KCNA5
(NM_002234.3) mutation was performed by PCR amplification using a
primer pair spanning the p.D322H (c.964 GNC) mutation in exon 1 of
the KNCA5 gene (see Table 2).
RNA extraction and RT-PCR analysis
Total RNA was extracted using Quick-RNA MiniPrep (Zymo Re-
search), and quantified. Reverse transcriptase-PCR of 1 μg of total RNA
was carried out using with iScript cDNA Synthesis Kit (BIO-RAD),
followed by specific PCR amplification. Sequences of individual primer
pairs are detailed in Table 2. PCR products were visualized by agarose/
ethidium bromide gel electrophoresis.
Molecular analysis
The expression of endogenous pluripotency-related genes OCT4,
SOX2, and NANOG was assessed by quantitative PCR (qPCR) using the
primers reported in Table 2. The expression ratio of the target genes
was calculated by using the 2−ΔΔCt method, considering GAPDH as ref-
erence gene.
Embryoid body formation assay of pluripotency
For the generation of EBs, UNIBSi001-A cells were resuspended in
DMEM/F12 medium supplemented with 20% FBS, 0.1 mM NEAA,
1 mM L-Glutamine, 50 μM 2-mercaptoethanol, 50 U/mL penicillin and
50 mg/mL streptomycin (all from Thermo Fisher Scientific). Seven
days later, EBs were transferred onto 0.1% gelatin-coated glass and cul-
tured for additional 14 days. Then, cellswere fixed using 4% paraformal-
dehyde and stained.
Immunofluorescence staining
The cells were incubated with Blocking Buffer (PBS containing 3%
Donkey serum, 0.1% Triton X-100) for 60 min at room temperature.
Next, primary antibodies, listed in Table 2, diluted in blocking buffer
were added and incubated O/N at 4 °C. After extensive washing, Alexa
Fluor 594- and/or Alexa Fluor 488-conjugated secondary antibodiesData
Not shown but
available with author
X2, NANOG, SSEA3, and Tra-1-81 Fig. 1 panel E
9% and Tra-1-81: 94.3% Fig. 1 panel F
Fig. 1 panel B
Supplementary file
Fig. 1 panel C
lysis Fig. 1 panel A
oprotein (endodermal germ layer), beta III Tubulin
Muscle Actin (mesodermal germ layer).
Fig. 1 panel E
Table 2
Antibodies used for immunocytochemistry and flow cytometry.
Antibody Dilution Company Cat # and RRID
Pluripotency marker Mouse anti-OCT3/4 1:60 Santa Cruz, Cat#sc5279
RRID: AB_628051
Pluripotency marker Mouse anti-SOX2 1:200 R&D, Cat#MAB2018
RRID: AB_358009
Pluripotency marker Goat anti-NANOG 1:200 Everest Biotech, Cat#EB06860
RRID: AB_2150379
Pluripotency marker Mouse anti-Tra-1-81 1:200 Millipore, Cat#MAB4381
RRID: AB_177638
Pluripotency marker Rat anti-SSEA3 1:100 DSHB, Cat#MC-631
RRID: AB_528476
Pluripotency marker Mouse anti-SSEA4 1:200 R&D, Cat#FAB1435P
RRID: AB_357038
Differentiation markers Rabbit anti-AFP 1:400 DAKO, Cat# A0008
RRID: AB_2650473
Differentiation markers Mouse anti-βIIITub 1:500 Sigma-Aldrich, Cat# T8660,
RRID: AB_477590
Differentiation markers Mouse anti-αSMA 1:300 Thermo Fisher Scientific/Lab Vision, Cat# MS-113-P1, RRID: AB_64002
Secondary antibodies Goat anti-rat IgM 594 1:600 Invitrogen, Cat#A21213
RRID: AB_11180463
Secondary antibodies Goat anti-mouse IgM 594 1:600 Invitrogen, Cat#A21044
RRID: AB_2535713
Secondary antibodies Donkey anti-mouse IgG 488 1:600 Invitrogen, Cat#A21202
RRID: AB_2535788
Secondary antibodies Donkey anti-goat 488 IgG 1:600 Invitrogen, Cat#A11055
RRID: AB_2534102
Secondary antibodies Donkey anti-rabbit 488 IgG 1:600 Invitrogen, Cat#A21206
RRID: AB_2535792
Primers
Target Forward/reverse primer (5′-3′)
SeV genome sequence (qPCR) SeV GGATCACTAGGTGATATCGAGC/ACCAGACAAGAGTTTAAGAGATATGTATC
Pluripotency markers (qPCR) OCT3/4 GGGTTTTTGGGATTAAGTTCTTCA/GCCCCCACCCTTTGTGTT
Pluripotency markers (qPCR) SOX2 CAAAAATGGCCATGCAGGTT/AGTTGGGATCGAACAAAAGCTATT
Pluripotency markers (qPCR) NANOG AGGAAGACAAGGTCCCGGTCAA/TCTGGAACCAGGTCTTCACCTGT
House-keeping genes (qPCR) GAPDH GAAGGTCGGAGTCAACGGATT/TGACGGTGCCATGGAATTTG
Targeted mutation analysis/sequencing PITX2c ACTGTGGCATCTGTTTGCT/GACGACATGCTCATGGAC
32 C. Mora et al. / Stem Cell Research 24 (2017) 29–32(ThermoFisher Scientific)were added 1 h at room temperature. Cellular
nuclei were counterstained with DAPI. The cells were observed under
an inverted fluorescent microscope (Axiovert, Zeiss).
Flow cytometry
The cells were stained with either anti-SSEA4-PE antibody (BD Bio-
science) orwith anti Tra-1-81 antibody (Millipore), followed by incuba-
tions with a biotinylated anti mouse IgM and a PE-conjugated
streptavidine. Samples were analyzed using FACSCanto™ flow cytome-
try (BD Bioscience).
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